The agency has provisionally determined that Selarsdi will be interchangeable with Stelara following the exclusivity ... for subcutaneous injection at 45 mg/0.5 mL and 90 mg/mL, a single-dose ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous ... pharmacokinetics and immunogenicity to the reference drug Stelara® in patients with moderate to severe plaque psoriasis.